Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2). J of Skin [Internet]. 2020 Oct. 27 [cited 2026 Apr. 19];4(6):s96. Available from: https://skin.dermsquared.com/skin/article/view/1066